Abstract Library

#4651 Neuroendocrine hyperplasia of infancy (NEHI) vs. diffuse idiopathic pulmonary neuroendocrine cell hyperplasia (DIPNECH): What is the difference?

Introduction: Neuroendocrine Hyperplasia of Infancy (NEHI) is a rare disease that belongs to the group of interstitial lung disease in children; characterised by hypoxemia, tachypnoea, and respiratory distress, often misdiagnosed as reactive airway disease or bronchiolitis. The diagnosis relies on histologic evaluation. We describe the clinical presentation and paraclinical characteristics of paediatric patients with NEHI.

Conference:

Presenting Author:

Authors: González Devia D, Restrepo Gualteros S, Ortiz Pérez M, Fernández Hernández B,

Keywords: Neuroendocrine Hyperplasia of Infancy, Diffuse idiopathic pulmonary neuroendocrine cell hyperplasia, child,

#4551 Characterisation and management of neuroendocrine tumours: Findings from a prospective study in Algeria

Introduction: Gastrointestinal neuroendocrine tumours are characterised by varied clinical presentations and behaviours. Their increasing incidence highlights the need for better understanding and management strategies.

Conference:

Presenting Author:

Authors: Zerrouk D, Boukerzaza I, Laouar N, Kassama Z, Mansouri F,

Keywords: Neuroendocrine neoplasm, Observational Study, Treatment Outcomes,

#4470 Demystifying DIPNECH: Updates from a new longitudinal patient registry

Introduction: Diffuse idiopathic pulmonary neuroendocrine cell hyperplasia (DIPNECH) was first characterised in 1992 with a case series describing 6 patients with neuroendocrine cell hyperplasia, with cough and dyspnoea. Since that time, DIPNECH has remained understudied.

Conference:

Presenting Author:

Authors: Skotte E, Linden A, Libre M, Lippincott E, Cass A,

Keywords: DIPNECH,

#4460 Digestive neuroendocrine tumours G1 and G2: Experience of the medical oncology department at the Oran University Hospital Establishment 1st November 1954

Introduction: The histological classification of neuroendocrine tumours (NETs) remains complex, and their grading is a major prognostic factor, essential for guiding appropriate management. Moreover, NETs raise unresolved histogenetic questions. The treatment of grade 1 (G1) NETs primarily relies on somatostatin analogues, while grade 2 (G2) NETs, being more heterogeneous, may require management that includes chemotherapy or targeted therapy.

Conference:

Presenting Author:

Authors: Kehili H, Bengueddache A, Boumansour N, Larbi Bounsbia L, Bechikh A,

Keywords: Digestive Neuroendocrine Tumour, Grade 1, Grade 2, Somatostatin Analogue,

#4441 Gastric neuroendocrine neoplasms in younger patients: A retrospective single-centre study

Introduction: Gastric neuroendocrine neoplasms (gNENs) are rare neoplasms arising from stomach enterochromaffin-like (ECL) cells. Type I gNENs are the most common type, typically indolent and arising in the context of chronic atrophic gastritis (CAG). While type I gNENs are generally diagnosed in pts over 50, their occurrence in younger pts raises concern about the onset of CAG-related complications at an earlier age, potentially affecting tumour growth and clinical outcomes. Young-oriented studies on type I gNETs are still lacking in literature.

Conference:

Presenting Author:

Authors: Romano E, Rinzivillo M, Marasco M, Dell' Unto E, Esposito G,

Keywords: Gastric neuroendocrine neoplasm, Young adults, Chronic Atrophic Gastritis,